Skip to main content
. 2024 Mar 15;14:6331. doi: 10.1038/s41598-024-54424-y

Table 2.

Clinical characteristics of psoriasis Patients with clear SARS-CoV-2 infection status.

Characteristic SARS-CoV-2 infection (n = 516) SARS-CoV-2 non-infection (n = 71) P-value
Subtype of psoriasis
 Psoriasis vulgaris 438 (84.9) 59 (83.1) 0.695
 Other subtypes of psoriasis* 78 (15.1) 12 (16.9)
Course of psoriasis, (years)
 ≤ 10 240 (46.5) 38 (53.5) 0.267
 > 10 276 (54.5) 33 (46.5)
Severity of psoriasis*
 Mild 105 (20.3) 22 (31.0) 0.041
 Moderate to severe 411 (79.7) 49 (69.0)
Nail impairment
 Yes 254 (49.2) 26 (36.6) 0.046
 No 262(50.8) 45 (63.4)
Unhealthy lifestyle habits*
 Yes 334 (64.7) 48 (67.6) 0.634
 No 182 (35.3) 23 (32.4)
Mental stress exacerbates psoriasis
 Yes 43 (8.3) 1 (1.4) 0.038
 No 473 (91.7) 70 (98.6)
Infection exacerbates psoriasis
 Yes 130 (25.2) 6 (8.5) 0.002
 No 386 (74.8) 65 (91.5)
Psoriasis treatment
 Oral systemic treatment 71 (13.8) 8 (11.3) 0.933
 Biological treatment 330 (63.9) 47 (66.2)
 Non-systemic treatment 82 (15.9) 12 (16.9)
 Not receiving treatment 33 (6.4) 4 (5.6)
Biologics
 Anti TNF-α 23 (4.5) 6 (8.5) 0.129
 Anti IL-12/23 65 (12.6) 13 (18.3)
 Anti IL-23 29 (5.6) 1 (1.4)
 Anti IL-17 213 (41.3) 27 (38.0)
Oral systemic treatment
 TCM* 36 (7.0) 3 (4.2) 0.306
 TYK2* 3 (0.6) 2 (2.8)
 Cyclosporin 2 (0.4) 0 (0.0)
 Acitretin 21 (4.1) 3 (4.2)
 Methotrexate 8 (1.6) 0 (0.0)
 Glucocorticosteroid 4 (0.8) 0 (0.0)

Values are presented as n (%) unless stated otherwise. Other subtypes of psoriasis*: include Psoriasis Arthritis, Pustular Psoriasis, Erythrodermic Psoriasis. Severity of psoriasis*: mild, BSA (body surface area) ≤ 3%; moderate to severe, BSA > 3%. Unhealthy lifestyle habit*: include smoking, alcohol consumption, bad diet, unlike exercising, poor sleep quality and others. TCM*: Traditional Chinese Medicine; TYK2*: TYK2, tyrosine kinase 2; TNF-α, tumor necrosis factor alpha; IL-12/23, interleukin-12 and 23; IL-23, interleukin-23; IL-17, interleukin-17.